Accelerated heart rate is a risk factor of general and cardiovascular mortality in different populations. The classical treatment to achieve heart rate reduction by β-blockers and calcium channel antagonists from the group of non-dihydropyridines (verapamil and diltiazem) is often limited by contraindications or adverse reactions. Ivabradine is a unique, modern drug, the mechanism of action of which is blocking the If current in the sinoatrial node. This translates into a reduction in heart rate – a parameter associated with poor prognosis in patients with heart failure. The following document contains the opinion of an expert group summarising current knowledge on ivabradine and its use in the population of patients with heart failure.